Last night Circadian Technologies signed a $10 million deal with private hospital operator Healthscope to test and market a breakthrough cancer diagnostic tool. The technology, which helps identify the source of secondary cancers, will be commercially available within months.
On top of this impressive news, Circadian said it expected to make several more announcements of a similar nature this year.
Amid all the bad results being reported recently, Circadian s half-year results showed cash reserves of $42.1 million.
Healthscope, meanwhile, posted a 145% rise in first half profit, and a 13.9% increase in revenue, lending weight to the theory that the biotech and health care sectors traditionally weather economic adversity fairly well.
Back in October, biotech expert David Langsam analysed several stocks and identified many investment opportunities. Click here to read the article
Stocks for your watch list:
- Circadian Technologies: CIR.AX (ASX)
- Progen Pharmaceuticals: PGL.AX (ASX); PGLA.O (NASDAQ)
- Cochlear: COH.AX (ASX)
- CSL: CSL.AX (ASX)
- ResMed: RMD:AX (ASX); RMD.N (NYSE)
- Healthscope: HSP.AX (ASX)
Further information:
